The human epidermal growth factor receptor-2 (HER2) is a cell surface receptor tyrosine kinase that is markedly amplified or over-expressed in approximately 20–30% of BC tumors and serves as a prognostic and predictive biomarker, as it is mainly is associated with a poor clinical outcome. Here, ERBB2 is linked to breast cancer.